Rating History for Emergent BioSolutions (EBS) by JPMorgan
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 8/21/2026 | Jessica Fye | New Coverage | Underweight (N/A) |
N/A (N/A) |
4.89 (6.22) |
27.2% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 8/21/2026 | Jessica Fye | New Coverage | Underweight (N/A) |
N/A (N/A) |
4.89 (6.22) |
27.2% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||